2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urologic Diseases
1
Nephritis
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Kidney Diseases
1
Immune System Diseases
1
Heart Failure
1
Glomerulonephritis, IGA
1
Glomerulonephritis
1
Cardiomyopathies
1
Autoimmune Diseases
1
Interventions
telitacicept
3
fludarabine
3
Prednisone
3
Data Collection
3
Cyclophosphamide
3
Specimen Handling
2
Nivolumab
2
Blood Specimen Collection
2
Antilymphocyte Serum
2
thymoglobulin
1
remdesivir
1
prednylidene
1
human papillomavirus vaccine, L1 type 16, 18
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
cabozantinib
1
apremilast
1
Watchful Waiting
1
Vitamin D
1
Valsartan
1
Telemedicine
1
Surveys and Questionnaires
1
Standard of Care
1
Pyridostigmine Bromide
1
Practice Guidelines as Topic
1
Population Groups
1
Platinum Compounds
1
Plasma Exchange
1
Phlebotomy
1
Peripheral Blood Stem Cell Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Autoimmune Diseases
×
Valsartan
×
Clear all
NCT02765594
2017-09-20
HCQIgAN
Peking Union Medical College Hospital
Phase 4
Unknown
98 enrolled